Flux G - Search Results

1

Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project.

Taprogge J, Vergara-Gil A, Leek F, Abreu C, Vávrová L, Carnegie-Peake L, Schumann S, Eberlein U, Lassmann M, Schurrat T, Luster M, Verburg FA, Vallot D, Vija L, Courbon F, Newbold K, Bardiès M, Flux G. Taprogge J, et al. Among authors: flux g. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3225-3234. doi: 10.1007/s00259-023-06295-0. Epub 2023 Jun 10. Eur J Nucl Med Mol Imaging. 2023. PMID: 37300572 Free PMC article.

2

Quantitative PET and SPECT performance characteristics of the Albira Trimodal pre-clinical tomograph.

Spinks TJ, Karia D, Leach MO, Flux G. Spinks TJ, et al. Among authors: flux g. Phys Med Biol. 2014 Feb 7;59(3):715-31. doi: 10.1088/0031-9155/59/3/715. Phys Med Biol. 2014. PMID: 24442479

3

A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy.

Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, Flux GD, Sgouros G. Hobbs RF, et al. Among authors: flux gd. Phys Med Biol. 2012 May 21;57(10):3207-22. doi: 10.1088/0031-9155/57/10/3207. Epub 2012 May 1. Phys Med Biol. 2012. PMID: 22546715 Free PMC article.

4

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.

Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Gaze MN, et al. Cancer Biother Radiopharm. 2005 Apr;20(2):195-9. doi: 10.1089/cbr.2005.20.195. Cancer Biother Radiopharm. 2005. PMID: 15869455

5

A generalized 4D image registration scheme for targeted radionuclide therapy dosimetry.

Papavasileiou P, Divoli A, Hatziioannou K, Flux GD. Papavasileiou P, et al. Cancer Biother Radiopharm. 2007 Feb;22(1):160-5. doi: 10.1089/cbr.2007.310. Cancer Biother Radiopharm. 2007. PMID: 17627425

6

Molecular radiotherapy--the radionuclide raffle?

Gaze MN, Flux GD. Gaze MN, et al. Among authors: flux gd. Br J Radiol. 2010 Dec;83(996):995-7. doi: 10.1259/bjr/32706189. Br J Radiol. 2010. PMID: 21088085 Free PMC article. No abstract available.

7

Biologically effective dose in fractionated molecular radiotherapy--application to treatment of neuroblastoma with (131)I-mIBG.

Mínguez P, Gustafsson J, Flux G, Gleisner KS. Mínguez P, et al. Among authors: flux g. Phys Med Biol. 2016 Mar 21;61(6):2532-51. doi: 10.1088/0031-9155/61/6/2532. Epub 2016 Mar 7. Phys Med Biol. 2016. PMID: 26948833

8

Molecular radiotheranostics for neuroendocrine tumours.

Navalkissoor S, Flux G, Bomanji J. Navalkissoor S, et al. Among authors: flux g. Clin Med (Lond). 2017 Oct;17(5):462-468. doi: 10.7861/clinmedicine.17-5-462. Clin Med (Lond). 2017. PMID: 28974600 Free PMC article.

9

The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.

Flux G, Bardies M, Monsieurs M, Savolainen S, Strands SE, Lassmann M; EANM Dosimetry Committee. Flux G, et al. Z Med Phys. 2006;16(1):47-59. doi: 10.1078/0939-3889-00291. Z Med Phys. 2006. PMID: 16696370 Review.

10

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

Flux G, Bardies M, Chiesa C, Monsieurs M, Savolainen S, Strand SE, Lassmann M. Flux G, et al. Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1699-700. doi: 10.1007/s00259-007-0471-9. Eur J Nucl Med Mol Imaging. 2007. PMID: 17565497 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

143 results

Search Page

Filters